Role of GABAA receptors in cognition

Biochemical Society Transactions

Volumn 37, Issue 6, 2009, Pages 1328-1333

  Möhler, Hanns ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

aminobutyric acid type A receptor (GABAA receptor); Anxiety; Benzodiazepine; Cognition; Pain; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; 6 FLUORO 2,9 DIHYDRO 9 METHYL 2 PHENYL 4 (1 PYRROLIDINYLCARBONYL) 1H PYRIDO[3,4 B]INDOL 1 ONE; 7 TERT BUTYL 3 (2,5 DIFLUOROPHENYL) 6 (2 METHYL 2H 1,2,4 TRIAZOL 3 YLMETHOXY) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; ANXIOLYTIC AGENT; BENZODIAZEPINE; CENTRAL NERVOUS SYSTEM AGENTS; DIAZEPAM; ELB 139; ETOMIDATE; GABOXADOL; INDIPLON; L 655708; MK 0777; NS 11394; OCINAPLON; TPA 003; TPA 023; UNCLASSIFIED DRUG; ZALEPLON; ZOLPIDEM; 4 AMINOBUTYRIC ACID; ISOPROTEIN; LIGAND;

ARTICLE; CHRONIC PAIN; COGNITIVE DEFECT; ELECTROENCEPHALOGRAM; GABAERGIC SYSTEM; HUMAN; INTERNEURON; LEARNING; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; SCHIZOPHRENIA; SEDATION; SPATIAL MEMORY; TRANQUILIZING ACTIVITY; ANIMAL; ANXIETY; BRAIN; COGNITION; CYTOLOGY; ELECTROENCEPHALOGRAPHY; GENETICS; MEMORY; METABOLISM; MOUSE; NERVE CELL NETWORK; PAIN; PHYSIOLOGY; SLEEP;

ANIMALS; ANXIETY; BRAIN; COGNITION; ELECTROENCEPHALOGRAPHY; GAMMA-AMINOBUTYRIC ACID; HUMANS; INTERNEURONS; LEARNING; LIGANDS; MEMORY; MICE; NERVE NET; PAIN; PROTEIN ISOFORMS; RECEPTORS, GABA-A; SCHIZOPHRENIA; SLEEP;

EID: 70450182120     PISSN: 03005127     EISSN: 14708752     Source Type: Journal    
DOI: 10.1042/BST0371328     Document Type: Article

References (56)

1. Buzsaki, G. and Draguhn, A. (2004) Neuronal oscillations in cortical networks. Science 304, 1926-1929
2. Klausberger, Th. and Somogyi, P. (2008) Neuronal diversity and temporal dynamics: the unity of hippocampal circuit operations. Science 321, 53-57
3. Möhler, H. and Okada, T. (1977) Benzodiazepine receptor: demonstration in the central nervous system. Science 198, 849-851
4. A receptors. J. Neurochem. 102, 1-12
5. A receptors: classification on the basis of subunit structure and receptor function Pharmacol. Rev. 50, 291-313
6. A receptor subtypes. In The GABA receptors, 3rd edn (Enna, S.J. and Möhler, H., eds), pp. 23-40, Humana Press, Totowa
7. A receptor subtypes. Nature 401, 796-800
8. Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J.A., Fritschy, J.M., Rülicke, T., Bluethmann, H., Mahler, H. and Rudolph, U. (2000) Molecular and neuronal substrate for the selective attenuation of anxiety. Science 290, 131-134
9. A receptors. Proc. Natl. Acad. Sci. U.S.A. 99, 8980-8985
10. A receptor α1 subtype. Nat. Neurosci. 3, 587-592
11. A receptor-ion channels. J. Med. Chem. 45, 1887-900
12. A receptors to a dopamine hyperfunction. Proc. Natl. Acad. Sci. U.S.A. 102, 17154-17159
13. A receptors in mediating the anxiolytic effects of benzodiazepines. J. Neurosci. 25, 10682-10688
14. A receptors. Handb. Exp. Pharmacol. 169, 225-247
15. A receptor subtypes in the brain: a paradigm for CNS drug discovery? Drug Discov. Today 8, 445-450
16. 3 GABAA receptor subtypes mediate the anxiolytic properties of benzodiazepine site ligands in the conditioned emotional response paradigm. Eur. J. Neurosci. 23, 2495-2504
17. A receptors. Br. J. Pharmacol. 144, 357-366
18. Licata, S.C. and Rowlett, J.K. (2008) Abuse and dependence liability of benzodiazepine-type drugs: GABAA receptor modulation and beyond. Pharmacol. Biochem. Behav. 90, 74-89
19. A receptor subtype functions. Curr. Opin. Pharmacol. 6, 18-23
20. 5 selective cognition enhancer. CNS Neurosci. Ther. 14, 25-35
21. A receptor. J. Neurosci. 22, 5572-5580
22. 5 receptors with cognition enhancing properties. J. Med. Chem. 47, 5829-5832
23. 5 subtype benzodiazepine receptor inverse agonist. Neuropharmacology 53, 810-820
24. A receptor subtypes with special reference to memory function and neurological disorders. In Excitatory inhibitory balance: synapses, circuits and systems plasticity. (Hensch, T.K. and Fagiolini, M., eds), pp. 215-228, Kluwer Academic/Plenum Publishers, New York
25. Stephan, K.E., Friston, K.J. and Frith, C.D. (2009) Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring schizophrenia. Schizophr. Bull. 35, 509-527
26. Lewis, D.A., Cho, R.Y., Carter, C.S., Erklund, K., Forster, S., Kelly, M.A. and Montrose, D. (2008) Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia. Am. J. Psychiatry 165, 1585-1593
27. A receptor subtypes demonstrated in hippocampal and olfactory neurons in vivo. Neurosci. Lett. 249, 99-102
28. A receptor subtypes. Nature 451, 330-334
29. A receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy. J. Pharmacol. Exp. Ther. 327, 954-968
30. A receptor-positive allosteric modulator NS11394 with diazepam, zolpidem, bretazenil and gaboxadol in rat models of inflammatory and neuropathic pain. J. Pharmacol. Exp. Ther. 327, 969-981
31. Zeilhofer, H.U., Möhler, H. and Di Lio, A. (2009) GABAergic analgesia: new insights from mutant mice and subtype-selective agonists. Trends Pharmacol. Sci. 30, 397-402
32. A receptor subtype. Proc. Natl. Acad. Sci. U.S.A. 98, 6464-6469
33. A receptor subtype and state specificity. Proc. Natl. Acad. Sci. U.S.A. 101, 3674-3679
34. Kopp, C., Rudolph, U. and Tobler, I. (2004) Sleep EEG changes after zolpidem in mice. NeuroReport 15, 2299-2302
35. A-benzodiazepine receptors as targets for new hypnotics. in Sleep Disorders: Diagnosis and Therapeutics (Pandi-Perumal, S.R., Verster, J.C., Monti, J.M., Lader, M. and Langer, S.Z., eds), pp. 206-219, Informa Healthcare, London
36. A receptors. Br. J. Pharmacol. 136, 965-974
37. Storustovu, S. and Ebert, B. (2003) Gaboxadol: in vitro interaction studies with benzodiazepines and ethanol suggest functional selectivity. Eur. J. Pharmacol. 467, 49-56
38. A receptor function. Angew. Chem. Int. Ed. 111, 2852-2864
39. Huckle, R. (2004) Gaboxadol: Lundbeck/Merck. Curr. Opin. Invest. Drugs 5, 766-773
40. A receptors different from zolpidem, zopiclone and benzodiazepines. Neurosci. Res. Commun. 25, 139-148
41. Foster, A.C., Pelleymounter, M.A., Cullen, M.J., Lewis, D., Joppa, M., Chen, T.K., Bozigian, H.P., Gross, R.S. and Gogas, K.R. (2004) In vivo pharmacological characterization of indiplon, a novel pyrazolopyrimidine sedative-hypnotic. J. Pharmacol. Exp. Ther. 311, 547-559
42. A receptor modulator. Proc. Natl. Acad. Sci. U.S.A. 102, 7380-7385
43. A receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasms. CNS Drug Rev. 9, 3-20
44. Knabl, J., Zeilhofer, U.B., Crestani, F., Rudolph, U. and Zeilhofer, H.U. (2009) Genuine antihyperalgesia by systemic diazepam revealed by experiments in GABA-A receptor point-mutated mice. Pain 141, 233-238
45. A receptors, is a non-sedating anxiolytic in rodents and primates. J. Pharmacol. Exp. Ther. 316, 410-422
46. A receptor. J. Pharmacol. Exp. Ther. 314, 717-724
47. 5 receptor inverse agonists as condition enhancers. J. Med. Chem. 47, 2176-2179
48. 5 subunit in social encounters between male mice. Aggressive Behav. 30, 319-325
49. A receptor enhances cognition. J. Pharmacol. Exp. Ther. 316, 1335-1345
50. 3δ γ-aminobutyric acid type A receptors at low concentration known to affect humans. Proc. Natl. Acad. Sci. U.S.A. 100, 15218-15223
51. A receptor. Nat. Rev. Neurosci. 6, 565-575
52. Rudolph, U. and Antkowiak, B. (2004) Molecular and neuronal substrates for general anaesthetics. Nat. Rev. Neurosci. 5, 709-720
53. A agonists and partial agonists: THiP (Gaboxadol) as a non-opioid analgesic and a novel type of hypnotic. Biochem. Pharmacol. 68, 1573-1580
54. Haefely, W., Martin, J.R. and Schoch, P. (1990) Novel anxiolytics that act as partial agonists at benzodiazepine receptors. Trends Pharmacol. Sci. 11, 452-456
55. Atack, J.R., Pike, A., Marshall, G., Stanley, J., Lincoln, R., Cook, S.M., Lewis, R.T., Blackaby, W.P., Goodacre, S.C., McKernan, R.M. et al. (2006) The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxypagoclone. Neuropharmacology 50, 677-689
56. A receptor channels from low- to high-efficacy gating patterns. J. Neurosci. 23, 10934-10943